- Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
- First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
- Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
- Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
- Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
More ▼
Key statistics
On Friday, Kyverna Therapeutics Inc (KYTX:NSQ) closed at 15.25, 9.24% above its 52-week low of 13.96, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.86 |
---|---|
High | 16.44 |
Low | 14.81 |
Bid | 14.90 |
Offer | 16.43 |
Previous close | 15.03 |
Average volume | 502.35k |
---|---|
Shares outstanding | 43.12m |
Free float | 38.49m |
P/E (TTM) | -- |
Market cap | 648.02m USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼